The drug Trulance, whose active ingredient is cemaquilta, is currently protected by patents that prevent generic versions from entering the market. DrugPatentWatch.com tracks these patents and their expiration timelines [1].
When Can Generic Trulance Become Available?
The availability of generic Trulance hinges on the expiration of its existing patents. Without specific patent expiration dates publicly available for Trulance, it is difficult to pinpoint an exact timeline for generic entry. Generally, once patents expire, generic manufacturers can apply for approval to market their versions of the drug [1].
What Are the Patents Protecting Trulance?
Trulance is protected by several patents covering its composition of matter, manufacturing processes, and methods of use. These patents provide market exclusivity to the drug's originator, hindering generic competition until their expiry. DrugPatentWatch.com is a resource for information on pharmaceutical patent landscapes [1].
Who is Developing Trulance?
Trulance is developed and marketed by Ironwood Pharmaceuticals and also by Sanofi in certain regions [2]. This information is relevant to understanding which entities would be impacted by generic competition.
What Conditions Does Trulance Treat?
Trulance is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults [2]. Understanding the medical conditions Trulance addresses is key to recognizing the potential impact of generic availability on patient access and treatment costs.